Pharmaceutical

Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition

Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.

Jul 10, 2024 - 04:00
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Morphic’s lead asset MORF-057 is being investigated in three IBD clinical trials, with data in ulcerative colitis expected next year.
Read the original article

Tags:

Previous Article

Moderna and Mitsubishi Tanabe link on mRNA vaccines in Japan

Next Article

UK pharma group reprimands Novo Nordisk for undisclosed payments

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Teladoc stock slides despite business growth, Medtronic CEO talks innovation

STAT+: Teladoc stock slides despite business growth, Me...

Oct 26, 2023

Genespire raises $52m in Series B to trial paediatric gene therapy

Genespire raises $52m in Series B to trial paediatric g...

Sep 26, 2024

NIH nominee Bertagnolli will get a confirmation hearing next month, Sanders says

NIH nominee Bertagnolli will get a confirmation hearing...

Sep 8, 2023